Protalix BioTherapeutics
PLX
PLX
76 hedge funds and large institutions have $30.9M invested in Protalix BioTherapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
63% less call options, than puts
Call options by funds: $99K | Put options by funds: $269K
Holders
76
Holding in Top 10
–
Calls
$99K
Puts
$269K
Top Buyers
| 1 | +$5.73M | |
| 2 | +$403K | |
| 3 | +$333K | |
| 4 |
MSFS
Main Street Financial Solutions
Newtown,
Pennsylvania
|
+$287K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$256K |
Top Sellers
| 1 | -$868K | |
| 2 | -$665K | |
| 3 | -$501K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$394K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$213K |
